Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sapporo Clinical Laboratory's EBIT per Share for the
six
months ended in Sep. 2025 was 円125.84.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 was 円241.04.
During the past 12 months, the average EBIT per Share Growth Rate of Sapporo Clinical Laboratory was 32.70% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -20.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -9.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -5.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sapporo Clinical Laboratory's EBIT per Share or its related term are showing as below:
TSE:9776'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -21.7 Med: 5 Max: 23.9
Current: -20.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sapporo Clinical Laboratory was 23.90% per year. The lowest was -21.70% per year. And the median was 5.00% per year.
TSE:9776's 3-Year EBIT Growth Rate is not ranked
in the Healthcare Providers & Services industry.
Industry Median: 12
vs TSE:9776: -20.60
Sapporo Clinical Laboratory (TSE:9776) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sapporo Clinical Laboratory EBIT per Share Related Terms
Sapporo Clinical Laboratory EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円241.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sapporo Clinical Laboratory (TSE:9776) has a EBIT per Share of 円241.04 as of Sep. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sapporo Clinical Laboratory and its competitors.
Is Sapporo Clinical Laboratory's EBIT per Share too high?
Sapporo Clinical Laboratory's current EBIT per Share is 円241.04. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's EBIT per Share compare to competitors?
Sapporo Clinical Laboratory's EBIT per Share of 円241.04 can be compared against companies in the Healthcare Providers & Services industry. The industry median EBIT per Share is 12.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 12.00, based on 525 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sapporo Clinical Laboratory and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 12.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sapporo Clinical Laboratory's current EBIT per Share is 円241.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current EBIT per Share of 円241.04. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current EBIT per Share is 円241.04. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current EBIT per Share is 円241.04 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?
Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued.
The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.
Key valuation signals for TSE:9776:
EBIT per Share: 円241.04
GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score
Get the complete analysis for TSE:9776
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:9776 has been successfully added to your 
